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SUMMARY – Breast cancer is the most common malignancy in females. Despite its well-estab-
lished prognostic factors, our prognostic ability at an individual patient level remains limited. In this 
study, the immunohistochemical expression of B-Myb and DNA topoisomerase 2-alpha (Topo2a) 
was analyzed in primary tumors to identify patients with a higher risk of disease recurrence after ad-
juvant chemotherapy for early invasive breast cancer. We analyzed a cohort of 215 early invasive breast 
cancer patients having undergone surgery from 2002 to 2003 at the Zagreb University Hospital Cen-
tre, including 153 patients treated with adjuvant chemotherapy. All of them were followed-up pro-
spectively for at least ten years according to routine institutional practice. Statistically significant cor-
relations were found between B-Myb and Topo2a expression levels and particular well-established 
prognostic factors. B-Myb expression was lower in estrogen receptor (ER)-positive tumors (p=0.0773), 
whereas larger tumors and those with positive lymphovascular invasion displayed a statistically sig-
nificantly higher B-Myb expression (p=0.0409 and p=0.0196). Higher tumor grade indicated higher 
Topo2a values (p=0.0102 and p=0.0069). The subgroup with the expression of both proteins above the 
median value had an almost statistically significantly (p=0.0613) inferior prognosis compared to the 
rest of the cohort. Study results showed the B-Myb and Topo2a expression to have a prognostic value 
in breast cancer patients after adjuvant chemotherapy, which should be additionally explored in future 
studies in a larger patient cohort.
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Introduction
Breast cancer is a histologically, molecularly, and 
clinically heterogeneous disease, with molecular sub-
groups having different therapeutic approaches, prog-
nosis, and response to therapy. Tumor metastatic po-
tential is determined by several prognostic factors such 
as steroid receptor expression, HER-2/neu expression, 
and Ki-67 proliferation index.
In recent years, tumor proliferation markers and 
proliferative activity have been extensively investigated 
as potential survival and treatment response markers 
in breast cancer. Proliferative activity can be deter-
mined by several methods such as mitotic index, 
3H-thymidine index, flow-cytometry (detecting the 
number of cells in S-phase), immunohistochemistry 
methods (detecting cell cycle-specific proteins), and 
more recently, gene expression profiling studies1,2.
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The B-Myb is a transcription factor involved in cell 
cycle progression. Numerous cytogenetic analyses have 
identified B-MYB amplification or overexpression in 
breast3, liver4 and ovarian carcinomas5, as well as cuta-
neous T lymphomas6. Higher levels of B-Myb are as-
sociated with shortened overall survival (OS) and poor 
prognosis in breast cancer patients7. B-Myb expression 
is a sign of aggressive breast cancer and its overexpres-
sion in different breast cancer subtypes is associated 
with a significantly shortened OS in locally treated 
luminal A, luminal B, and HER2+/ER- breast can-
cers8.
Topoisomerase 2-alpha (Topo2a) is a nuclear en-
zyme that controls topologic structure of DNA during 
transcription9. It is highly expressed in proliferating 
cells and consecutively correlates with malignancy. 
Additionally, TOP2A amplification leading to Topo2a 
overexpression results in an improved response to 
Topo2a inhibitors, whereas its deletion results in pri-
mary resistance to them10-12. Therefore, TOP2A has 
been extensively studied in breast13, prostate14, gastric15, 
and ovarian cancer16.
Several studies have shown that Topo2a overex-
pression served as a predictor of shorter disease-free 
survival (DFS), as well as specific survival and OS 
rates17-20. Also, Topo2a expression was analyzed in dif-
ferent breast cancer subtypes, with highly proliferative 
subtypes (triple negative, luminal B, and HER2) ex-
pressing higher levels of Topo2a, which is also a sign of 
breast cancer aggressiveness and worse prognosis13,21.
This study aimed to select patients and analyze 
their B-Myb and Topo2a expression levels to predict 
response to adjuvant therapy and outcomes. Such an 
approach would enable us to stratify patients into sub-
groups for escalation and de-escalation of adjuvant 
systemic treatment and select patients with poor prog-
nosis for the implementation of novel adjuvant sys-
temic therapy regimens.
Materials and Methods
Breast carcinoma patient cohort characteristics
Paraffin-embedded tumor tissue samples were ob-
tained from a consecutive series of 215 patients re-
ferred to the Zagreb University Hospital Centre, Za-
greb, Croatia, for primary surgical treatment (either 
mastectomy or quadrantectomy with axillary dissec-
tion) due to invasive breast carcinoma between Sep-
tember 2002 and September 2003. Adjuvant radiation 
therapy was performed according to the guidelines 
valid at the time this study began. Patients received 
adjuvant chemotherapy if axillary lymph node in-
volvement was present or absent with the presence of 
other poor prognostic factors (high tumor grade, large 
tumors, lymphovascular invasion, lack of hormone re-
ceptor expression) and adjuvant endocrine blockade as 
indicated by the hormone receptor status. Out of 215 
patients, only those treated with adjuvant chemother-
apy were included in the study (N=153), with prior 
neoadjuvant therapy as an exclusion criterion. Low-
risk patients were not treated with adjuvant chemo-
therapy and were thus excluded. All patients were 
regularly followed-up for at least ten years, according 
to routine standard institutional practice and with lo-
cal recurrence, distant metastases, or death as primary 
outcomes. Data on ten-year OS and DFS were col-
lected. Archival tumor tissue and follow-up informa-
tion were collected with the Institutional Review 
Board approval.
For all patients, data on tumor size, surrogate sub-
type, tumor grade (nuclear and histologic), HER-2 
status, hormone receptor expression (estrogen and 
progesterone receptor, ER and PR), axillary lymph 
node involvement, lymphovascular invasion, and adju-
vant treatment were obtained22,23. Immunohistochem-
istry for ER (H7096, Dako, Glostrup, Denmark), PR 
(M3569, Dako, Glostrup, Denmark), and HER2 
(Herceptest, Dako, Glostrup, Denmark) was per-
formed on formalin-fixed, paraffin-embedded tissue 
slides with standard avidin-biotin immunoperoxidase 
staining method on a Tech Mate automatic stainer 
(Dako, Glostrup, Denmark). Evaluation of staining 
 results was similar to that used in routine diagnostics, 
and samples were considered positive when 10% of the 
cells were stained with ER and PR. For HER2 status, 
tumors were considered positive if they scored 3+ 
 according to the HercepTest criteria, and dual silver in 
situ hybridization (SISH) with amplification at a ratio 
of ≥2.0 was used to segregate immunohistochemically 
equivocal (2+) results.
Tissue microarray blocks and immunohistochemical 
expression of Ki-67, B-Myb, and topoisomerase 2-alpha
Expression of Ki-67, B-Myb, and Topo2a was ana-
lyzed by immunohistochemical (IHC) staining on tis-
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sue microarray (TMA) blocks24. A special needle 
(SAKURA, Japan) was used to punch the highest cel-
lular density area of the primary tumor to build the 
tissue microarray with three cores of 0.2 cm in diam-
eter from each primary tumor paraffins. The Manual 
Arrayer (Beecher Instruments, Sun Prairie, Wisconsin, 
USA) was used to re-embed the cores into blank re-
cipient blocks with 60 samples on a single slide25,26. 
Sections (5 μm) were cut and mounted on a glass slide, 
deparaffinized in xylene, and rehydrated in a graded 
alcohol series. For antibody incubation, different dilu-
tions were used, i.e. anti-topoisomerase 2-alpha anti-
body (Abcam, clone EP1102Y, 1:100), anti-phospho-
B-Myb (Epitomics, Thr 487, clone EPR2204Y, 1:200), 
and MIB-1 (Dako, Glostrup, Denmark) antibody 
(1:50). The automated stainer standard protocol (Dako 
Universal Staining System, Glostrup, Denmark) was 
used and diaminobenzidine (DAB) was used for stain-
ing visualization on a section counter stained with he-
matoxylin. Palatal tonsil tissue was used as a positive 
control for B-Myb, and HeLa cell lysate for Topo2a. 
Breast cancer tissue slides incubated without primary 
antibody served as negative controls. Staining results 
were presented as the percentage of cells with positive 
nuclear staining for Ki-67 and Topo2a, and cytoplas-
mic and nuclear staining for B-Myb, as indicated in 
the manufacturer’s instructions.
Statistical analyses
Statistical analyses were performed using Statistica 
6.0 software. Values of Ki-67, B-Myb, and Topo2a 
were provided as continuous variables. Non-paramet-
ric tests (ANOVA, Kruskal-Wallis, Mann-Whitney U 
test) were carried out to test for differences in B-Myb 
and Topo2a expression according to other clinicopath-
ologic variables (nodal status, histologic grade, and 
HR status). Correlations of B-Myb and Topo2a with 
other continuous variables were tested using Spear-
man’s test. The Kaplan-Meier method was used to 
generate univariate survival curves. The Gehan-Wil-
coxon test was used to assess differences in DFS and 
OS as co-primary endpoints. The level of statistical 
significance was set at p<0.05.
Results
We analyzed the relationship between B-Myb and 
Topo2a expression and clinicopathologic characteris-
tics, along with the early breast cancer outcomes in a 
subgroup of 153 women treated with systemic adju-
vant chemotherapy. The majority of breast carcinoma 
patients were older than 50 (60.8%) and postmeno-
pausal (56.2%) at the time of diagnosis. Most tumors 
were T2 according to the TNM classification (58.2%). 
Histologic tumor grades were predominantly 2 
(44.4%) and 3 (44.4%), and positive axillary lymph 
nodes were found in less than 50% of patients. Positive 
hormone receptors were found in 60.5% and 51% of 
patients for ER and PR, respectively. This study was 
conducted before the era of adjuvant trastuzumab; 
therefore, HER-2 positive tumors were not treated 
with it.
Association of B-Myb and Topo2a expression  
with other clinical and pathologic tumor characteristics
In this cohort, the median B-Myb expression value 
was 12, while that of Topo2a was 22. In addition, there 
was a positive correlation between Ki-67 and Topo2a 
expression levels (p=0.0013) (Table 1). We found no 
association between B-Myb and Ki-67 expression. B-
Myb expression was significantly associated with tu-
mor size, whereby larger tumors showed higher B-
Myb expression (p=0.0196) (Table 1). Higher histo-
logic and nuclear grades (grades 2 and 3) displayed 
higher Topo2a values (p=0.0102 and p=0.0069, re-
spectively) (Table 2). B-Myb expression was lower in 
ER-positive tumors, without a statistically significant 
difference (p=0.0773) (Table 2). A significantly higher 
Table 1. Correlations of B-Myb and Topo-2a expression with other clinicopathologic variables
Tumor size (n=153) Ki67 (n=151) DFS (n=60) OS (n=152)
Sr p Sr p Sr p Sr p
Topo2a 0.0017 0.9827 0.2590 0.0013* - 0.4307 0.0005* - 0.2425 0.0023*
B-Myb 0.1884 0.0196* - 0.0164 0.8414 - 0.1422 0.2781 - 0.1601 0.0486*
*p<0.05; DFS = disease-free survival; OS = overall survival; Sr = Spearman correlation coefficient r
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expression of B-Myb was found in patients with lym-
phovascular invasion (p=0.0409) (Table 2).
Influence of B-Myb and Topo2a expression  
on clinical outcomes
Disease-free survival
At ten-year follow-up, almost 38% of patients had 
relapsed, with the majority of them relapsing in the 
first five years. DFS was 69.28% and 62.09% at five- 
and ten-year follow-up, respectively (Fig. 1B). B-Myb 
expression was higher in patients who relapsed than it 
was in those who did not, but this difference was at the 
border of statistical significance (p=0.0591) (Table 2). 
Topo2a expression has been associated with the occur-
rence of relapses. A higher level of Topo2a protein was 
associated with a shorter time to relapse (p=0.000591) 
(Table 1).
Overall survival
In this cohort, the 5-year OS was 83.7% (25 pa-
tients died) and 10-year OS 71.9% (43 patients died, 
Table 2. B-Myb and Topo-2a expression according to other clinicopathologic variables (Mann-Whitney U test)



































































































































































63.00 9.00 144.00 35.11 61.83 107.50 0.0155*
No anthracyclines 
(n=13)
20.00 5.00 117.00 39.38 35.84
*p<0.05; MWU = Mann-Whitney U test; SD= standard deviation
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whereas 58.1% of them died during the first five years 
after surgery). More than 80% of relapses and more 
than 58% of deaths occurred in the first 5 years after 
surgery (Fig. 1A). B-Myb expression was higher in pa-
tients who died in comparison to those still alive, but 
this difference was at the border of statistical signifi-
cance (p=0.0510) (Table 2).
Additionally, statistically significant correlations 
were observed between survival duration and B-Myb 
and Topo2a levels (Table 1). Survival time was shorter 
in breast cancers with higher B-Myb and Topo2a val-
ues (p=0.048699 and p=0.0002321, respectively) (Ta-
ble 1). Cases with Topo2a and B-Myb expression 
above median values (22 and 12, respectively) had 
lower OS than those with values under the median, 
but these results did not reach statistical significance 
(p=0.1954 and p=0.1703, respectively). Among the pa-
tients who died, a significantly longer survival was seen 
in those who had received anthracycline-based che-
motherapy (p=0.0156) (Fig. 2). Additionally, after the 
first 48 months, patients who had received anthra-
cyclines had higher OS than that those who had 
not received this treatment (Gehan-Wilcoxon test, 
p=0.0354) (Fig. 3).
Fig. 1. Ten-year overall survival (A) and disease-free survival (B) in the whole cohort (N=153).
Fig. 3. Overall survival at 48 months  
according to chemotherapy regimen  
(anthracycline vs. non-anthracycline).
Fig. 2. Length of survival among patients  
who died according to chemotherapy regimen 
(anthracycline vs. non-anthracycline).
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Clinical outcomes according to the combined expression  
of B-Myb and Topo2a
The cohort was subdivided into four subgroups 
 according to combined B-Myb and Topo2a expres-
sion, as follows: 0 subgroup, with B-Myb and 
Topo2a expression under median values (n=46); 
T subgroup, with only Topo2a above the median value 
(n=36); M subgroup, with only B-Myb above the 
 median value (n=32); and TM subgroup, with both 
B-Myb and Topo2a above median values (n=39). 
 Kaplan-Meier analysis of the survival curves for these 
four subgroups showed that they did not differ signifi-
cantly (p=0.2953). The TM subgroup showed inferior 
survival compared to the rest of the cohort (n=114), 
but this result was near statistical significance (p= 
0.0613) (Fig. 4).
Discussion
Breast cancer is not a single disease with several 
morphological features but a group of molecularly dis-
tinct neoplastic diseases, and molecular subgroups 
with different prognoses require different therapeutic 
approaches27. As per current treatment recommenda-
tions, adjuvant systemic therapy is based on tumor 
stage and biology. However, patient performance sta-
tus, comorbidities, and preferences should also be con-
sidered28.
Despite the use of different prognostic and predic-
tive factors, our ability to predict breast cancer progno-
sis in each individual patient is limited29. Therefore, 
identifying reliable and efficient prognostic factors re-
mains a major research effort in order to avoid over-
treating low-risk patients and enhance the efficacy of 
adjuvant treatment for those with worse prognosis. 
The major goal is to increase our understanding of 
breast cancer prognosis and develop systemic treat-
ments tailored on the basis of predictions of clinical 
outcomes and risk of recurrence based on tumor ag-
gressiveness. Multigene signature assays (MSA) have 
changed our risk prediction perspectives with a grow-
ing body of evidence, especially through new data pre-
dicting the benefits of adjuvant chemotherapy based 
on the results of multigene signature-based panels30.
Avoiding the toxicity of systemic treatment is a key 
goal in the clinical decision-making process. There is a 
lot of interest in systemic treatment toxicity avoidance. 
The 15th St Gallen International Breast Cancer Con-
ference, held in 2017 in Vienna, reviewed new evi-
dence on loco-regional and systemic therapies for 
early breast cancer and the Conference main topic was 
‘Escalating and Deescalating Treatment’31,32. The opti-
mal use of MSA divided the panelists, and although 
they agreed that all the available multigene assays pro-
vided valuable information on the prognosis and risk 
outside the low-risk subgroup, there was no consensus. 
By defining the risk, the assays could help us omit che-
motherapy in node negative hormone receptor positive 
HER2 negative early breast cancer. In node positive 
disease (with 1 to 3 lymph nodes involved), agreement 
among the panelists was lower, and additional data 
from current clinical trials in the node positive popula-
tion are expected to support the decision on chemo-
therapy31.
The use of MSA is not without an additional strain 
on the healthcare systems. According to real-world 
data, the use of the 21-gene assay resulted in short-
time incremental costs to the healthcare system, de-
spite lower use of adjuvant chemotherapy33. Great ef-
forts are also made to establish assays identifying indi-
viduals with micro-metastatic spread, as it may provide 
additional prognostic information. A very important 
tool in predicting early breast cancer outcomes could 
be identification of circulating tumor DNA (ctDNA) 
Fig. 4. Overall survival according to combined  
B-Myb and Topo2a expression: inferior result in those 
with expression of both proteins above the median value 
(n=39) as compared with the remaining patients 
(n=114) (p=0.0613).
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or circulating tumor cells (CTCs)34,35. The abovemen-
tioned approaches to identify patients with worse out-
comes are expensive and inappropriate for daily rou-
tine in many low- and middle-income countries. Ad-
ditionally, MSA are still not widely available in many 
countries.
Our small study provided real-world data on the 
outcomes of early, primary, operable, and invasive 
breast cancer (intermediate- and high-risk) patients 
treated with adjuvant chemotherapy (and radiotherapy 
and endocrine therapy, if indicated).
A limitation of the study was a small sample size, 
yet it displayed several advantages, e.g., all primary 
treatments were performed at a single institution (sur-
gery, chemotherapy, radiotherapy, and indication for 
endocrine therapy), and all patients were referred to 
our institution with early operable breast cancer over a 
relatively short period of one year. Thus, all patients 
were treated according to treatment recommendations 
valid in that period, thus increasing homogeneity of 
our study cohort. An additional value of our study was 
long prospective follow-up for more than a decade in 
all patients, according to the routine institutional 
guidelines, providing us with accurate 5- and 10-year 
survival rates.
We considered the IHC expression of two prolif-
eration markers with prognostic impact, Topo2a as an 
old and well-known prognostic marker and B-Myb as 
a novel prognostic marker, and found them to be over-
expressed in aggressive breast cancers. Several previous 
studies showed that Topo2a overexpression served as a 
predictor of shorter DFS, specific survival rates, and 
OS rates13-16. Remarkably, B-Myb is an inductor of 
TOP2A gene expression8.
Our study results showed that patients with breast 
cancers overexpressing B-Myb and Topo2a above the 
median levels based on IHC had worse prognosis than 
patients without overexpression of these two proteins. 
Our previous study also revealed that higher IHC 
 expression of B-Myb was linked to worse progno- 
sis (shorter DFS and OS)36, as also reported by Thorn-
er et al.8.
The results of our study require further validation 
in larger patient cohorts and within different adjuvant 
chemotherapy regimens (anthracycline vs. non-an-
thracycline, etc.). It would also be useful to carry out 
our analysis across different breast cancer subtypes (lu-
minal B vs. triple negative, etc.), as it could help us 
select patients with a higher risk of worse outcomes for 
escalation of adjuvant therapy with more aggressive or 
novel chemotherapy regimens. In some higher risk 
 patients, escalating adjuvant chemotherapy is an op-
tion, as seen in the addition of capecitabine in triple 
negative breast cancer after preoperative chemothe-
rapy (CREATE-X)37. However, sometimes it is ad-
vantageous to de-escalate adjuvant therapy. For exam-
ple, four courses of chemotherapy (with AC or pacli-
taxel) can be as good as more courses in terms of OFS 
and OS38.
In conclusion, our study provides further insight 
for investigation of the prognostic impact of B-Myb 
and Topo2a overexpression in breast cancer patients 
treated with adjuvant chemotherapy.
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Sažetak
PROGNOSTIČKA VRIJEDNOST TOPOIZOMERAZE 2-ALFA I B-MYB  
U RANOM RAKU DOJKE LIJEČENOM ADJUVANTNOM KEMOTERAPIJOM
Lj. Radmilović Varga, N. Dedić Plavetić, P. Podolski, D. Mijatović, A. Kulić i D. Vrbanec
Rak dojke je najčešći zloćudni tumor u žena. Unatoč dobro definiranim “tradicionalnim” prognostičkim čimbenicima 
naša mogućnost prognoze za svaku pojedinu bolesnicu je ograničena. U ovom istraživanju smo analizirali imunohistokemij-
sku izraženost B-Myb-a i DNA topoizomeraze 2-alfa (Topo2a) u primarnim tumorima kako bi se identificirale bolesnice s 
većim rizikom povrata bolesti nakon adjuvantne kemoterapije za rani invazivni rak dojke. Analizirana je kohorta od 215 
bolesnica s ranim invazivnim karcinomima dojke koje su operirane u Kliničkom bolničkom centru Zagreb od 2002. do 2003. 
godine, uključujući 153 bolesnice koje su liječene adjuvantnom kemoterapijom. Sve su praćene prospektivno najmanje deset 
godina prema rutinskoj kliničkoj praksi. Dokazali smo statistički značajne korelacije između razine izraženosti B-Myb i 
Topo2a te nekih „tradicionalnih” prognostičkih čimbenika. Izraženost B-Myb je bila niža u ER pozitivnim tumorima 
(p=0,0773), ali su veći tumori, kao i oni s pozitivnom limfovaskularnom invazijom imali statistički značajno veću izraženost 
proteina B-Myb (p=0,0409 i p =0,0196). Također, pokazali smo da veći gradus tumora ukazuje na višu vrijednost Topo2a 
(p=0,0102 i p=0,0069). Pokazali smo da podskupina bolesnica s izraženošću oba proteina iznad srednje vrijednosti ima  lošiji 
ishod bolesti u odnosu na ostatak skupine, ali rezultat je blizu granice statističke značajnosti (p=0,0613). Naše istraživanje je 
pokazalo prognostičku vrijednost kombinacije prekomjerne imunohistokemijske izraženosti B-Myb i Topo2a u bolesnica s 
rakom dojke nakon adjuvantne kemoterapije, što zaslužuje daljnja istraživanja na većim skupinama bolesnica.
Ključne riječi: Rak dojke, prognoza, ishod; Adjuvantna kemoterapija; B-Myb; Topo2a
